Please login to the form below

Not currently logged in
Email:
Password:

Xiidra

This page shows the latest Xiidra news and features for those working in and with pharma, biotech and healthcare.

Takeda sells blockbuster-in-waiting Xiirda to Novartis for $5.3bn

Takeda sells blockbuster-in-waiting Xiirda to Novartis for $5.3bn

Xiidra was first launched in the US in 2016, and generated sales of around $400m last year. ... Xiidra, with its unique dual benefits, is an example of the type of innovative advances we invest in for the benefit of patients," said Paul Hudson, CEO

Latest news

  • Shire files dry eye drug lifitegrast in Europe Shire files dry eye drug lifitegrast in Europe

    Analysts predict Xiidra could become a $1bn product. Shire is awaiting the go-ahead of lifitegrast in the EU, seeking approval for the would-be dry eye disease blockbuster. ... The Anglo-Irish company claimed approval for first-in-class LFA-1 antagonist

  • Shire licences Parion dry eye drug in $535m deal Shire licences Parion dry eye drug in $535m deal

    All told the deal could be worth up to $535m for North Carolina biotech Parion, while Shire adds to the pipeline behind its recently-approved dry eye disease therapy Xiidra (lifitegrast). ... That is a different mechanism of action to current drugs

  • Shire launches dry eye drug Xiidra in US Shire launches dry eye drug Xiidra in US

    Shire's recently-approved dry eye disease drug Xiidra is now available in the US, throwing down a challenge to Allergan's rival therapy Restasis. ... That gives Xiidra a broader label than Restasis (cyclosporine) that analysts suggest could catapult it

  • FDA finally approves Shire’s potential blockbuster Xiidra FDA finally approves Shire’s potential blockbuster Xiidra

    Xiidra is tipped to be a $1bn product and is one of the stars of the Ireland-based manufacturer's pipeline. ... The only prescription eye drop indicated for the treatment of both signs and symptoms of this condition, Xiidra (lifitegrast ophthalmic

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2018

    According to Bloomberg, the products Xiidra eyedrops for dry eye and Natpara for hypoparathyroidism may be considered as a source of funds to reduce the debt Takeda will incur in the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

#DemandDiversity: For International Women's Day, we ask... why do women often suffer from more side effects than men?
Women are largely prescribed exactly the same treatment regimens as men, with no account for the underlying differences in physiology and drug metabolism between the sexes....
Good design saves lives
Good design and creative thinking are essential if we are to improve on existing problems in new ways, which is why design and creativity within healthcare is vital. Health is...
Why you must understand the pricing of patient recruitment companies
Recruiting a diverse range of patients and engaging with them for your clinical trial isn’t an easy task, which means you might turn to patient recruitment companies, like us, who...

Infographics